Although effect sizes of serum S100B levels also correlated with mean age of schizophrenia subjects (Table 2), this effect seems to be related to illness duration (rmean age/illness duration = 0.96, p < 0.001; correlation according to Pearson, two-tailed p) since S100B effects sizes were calculated by comparing schizophrenia subjects to age-matched control subjects, hence excluding any impact of age per se. Here, S100B is linked to schizophrenia.